BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol. 2005;56:10-14. [PMID: 15782313 DOI: 10.1007/s00280-004-0963-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol. 2007;13:3806-3815. [PMID: 17657834 DOI: 10.3748/wjg.v13.i28.3806] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
2 Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. Cancer Treat Rev. 2014;40:701-715. [PMID: 24731471 DOI: 10.1016/j.ctrv.2014.02.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 6.1] [Reference Citation Analysis]
3 Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene. 2007;26:3661-3678. [PMID: 17530020 DOI: 10.1038/sj.onc.1210377] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
4 Rimassa L, Gullo G, Carnaghi C, Abbadessa G, Zuradelli M, Tronconi MC, Pressiani T, Santoro A. Chemotherapy with Mitomycin C and Capecitabine in Patients with Advanced Colorectal Cancer Pretreated with Irinotecan and Oxaliplatin. Tumori 2006;92:285-9. [DOI: 10.1177/030089160609200404] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
5 Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer. 2005;93:510-514. [PMID: 16091760 DOI: 10.1038/sj.bjc.6602733] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
6 Farhat FS. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 2007;24:137-46. [PMID: 17848736 DOI: 10.1007/BF02698032] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
7 Bayoglu İV, Yildiz I, Varol U, Cokmert S, Alacacıoğlu A, Kucukzeybek Y, Akyol M, Demir L, Dirican A, Tarhan O. Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. Contemp Oncol (Pozn) 2015;19:385-90. [PMID: 26793023 DOI: 10.5114/wo.2015.53374] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Foubert F, Matysiak-budnik T, Touchefeu Y. Options for metastatic colorectal cancer beyond the second line of treatment. Digestive and Liver Disease 2014;46:105-12. [DOI: 10.1016/j.dld.2013.07.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
9 Hofheinz RD, Beyer U, Al-Batran SE, Hartmann JT. Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives. Onkologie 2008;31:271-81. [PMID: 18497518 DOI: 10.1159/000122590] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
10 Townsend AR, Bishnoi S, Broadbridge V, Beeke C, Karapetis CS, Jain K, Luke C, Padbury R, Price TJ. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol 2013;36:49-52. [PMID: 22270106 DOI: 10.1097/COC.0b013e31823fe40e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
11 Nishiofuku H, Tanaka T, Aramaki T, Boku N, Inaba Y, Sato Y, Matsuoka M, Otsuji T, Arai Y, Kichikawa K. Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. Clin Colorectal Cancer. 2010;9:305-310. [PMID: 21208845 DOI: 10.3816/ccc.2010.n.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
12 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235. [PMID: 18069765 DOI: 10.3748/wjg.13.6231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Gundgaard MG, Soerensen JB, Ehrnrooth E. Third-line therapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 2007;61:1-13. [DOI: 10.1007/s00280-007-0573-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
14 Saint A, Evesque L, Falk AT, Cavaglione G, Montagne L, Benezery K, Francois E. Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal. Cancer Med 2019;8:6853-9. [PMID: 31524335 DOI: 10.1002/cam4.2558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Capdevila J, Ramos FJ, Macarulla T, Elez E, Tabernero J. The role of salvage treatment in advanced colorectal cancer. Crit Rev Oncol Hematol 2009;71:53-61. [PMID: 18977669 DOI: 10.1016/j.critrevonc.2008.09.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
16 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-5. [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
17 Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347. [PMID: 19785749 DOI: 10.1186/1471-2407-9-347] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
18 Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. European Journal of Cancer 2012;48:820-6. [DOI: 10.1016/j.ejca.2012.01.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
19 Kang EJ, Choi YJ, Kim JS, Kim ST, Park KH, Choi IK, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma: Chemotherapy in refractory colon cancer. Asia-Pacific Journal of Clinical Oncology 2010;6:286-91. [DOI: 10.1111/j.1743-7563.2010.01334.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
20 Dimou A, Syrigos KN, Saif MW. Is there a role for mitomycin C in metastatic colorectal cancer? Expert Opinion on Investigational Drugs 2010;19:723-35. [DOI: 10.1517/13543784.2010.485191] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
21 Damm R, Seidensticker R, Ulrich G, Breier L, Steffen IG, Seidensticker M, Garlipp B, Mohnike K, Pech M, Amthauer H. Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. BMC Cancer. 2016;16:509. [PMID: 27439702 DOI: 10.1186/s12885-016-2549-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
22 Vormittag L, Kornek GV, Gruhsmann B, Lenauer A, Föger A, Depisch D, Lang F, Scheithauer W. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer – a retrospective analysis. Anti-Cancer Drugs 2007;18:709-12. [DOI: 10.1097/cad.0b013e3280761a9d] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlø C, Jensen BV. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 2007;46:697-701. [PMID: 17562448 DOI: 10.1080/02841860601009455] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
24 Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol. 2009;26:32-37. [PMID: 18498064 DOI: 10.1007/s12032-008-9077-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
25 Yang X, Yang S, Mckimmey C, Liu B, Edgerton SM, Bales W, Archer LT, Thor AD. Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation. Carcinogenesis 2010;31:695-702. [DOI: 10.1093/carcin/bgq007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
26 Bester L, Meteling B, Pocock N, Pavlakis N, Chua TC, Saxena A, Morris DL. Radioembolization versus Standard Care of Hepatic Metastases: Comparative Retrospective Cohort Study of Survival Outcomes and Adverse Events in Salvage Patients. Journal of Vascular and Interventional Radiology 2012;23:96-105. [DOI: 10.1016/j.jvir.2011.09.028] [Cited by in Crossref: 90] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]